Chronic Recurrent Cellulitis

Patient Summary

Is this FDA-cleared for this use?

Not FDA-cleared for chronic cellulitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for chronic recurrent cellulitis is investigational and considered inappropriate.

What evidence exists?

Tier C (investigational). No published trials; only theoretical mention. Evidence-based therapy for chronic/recurrent cellulitis: identification and treatment of predisposing factors (lymphedema, tinea pedis, venous insufficiency, obesity), antibiotic prophylaxis (penicillin V 250 mg twice daily) per PATCH trial evidence, compression for lymphedema, treatment of acute episodes with appropriate antibiotics (cephalexin, dicloxacillin, cefadroxil; clindamycin or vancomycin if MRSA suspected). Leech therapy in active or chronic cellulitis is contraindicated as it introduces Aeromonas and disrupts the skin barrier.

Main risks

• Severe risk of worsening cellulitis or new bacterial superinfection from leech bites
• Aeromonas hydrophila infection layered on top of existing bacterial infection
• Bleeding from bite sites for 6 to 24 hours after detachment
• Sepsis or bacteremia in patients with skin barrier disruption
• Allergic reaction to leech saliva (uncommon)
• Worsening lymphedema or venous insufficiency from procedural trauma
• Delay of evidence-based antibiotic prophylaxis (penicillin V)
• Risk of necrotizing fasciitis if rapid spread occurs

Who should not consider this

• Patients with active cellulitis or any signs of skin infection (absolute contraindication)
• Patients with severe lymphedema or venous stasis ulcers
• Patients with diabetes and peripheral arterial disease
• Immunocompromised patients (HIV, transplant, chemotherapy)
• Patients on anticoagulants, with hemophilia, or with severe anemia
• Patients who have not been offered antibiotic prophylaxis (penicillin V per PATCH trial)

What to ask your clinician

• Have I been offered antibiotic prophylaxis (penicillin V 250 mg twice daily per PATCH trial)?
• Have predisposing factors been addressed (tinea pedis, lymphedema, venous insufficiency, obesity)?
• Am I a candidate for compression therapy for lymphedema?
• What evidence specifically supports leech therapy for chronic cellulitis?
• What is the realistic risk of triggering worse infection with leech bites?
• Is there an infection-control plan for the bite sites?
• Should I see infectious disease or vascular medicine instead?

When to seek urgent care

• Rapidly spreading redness, severe pain disproportionate to appearance (suspect necrotizing fasciitis — emergency)
• Crepitus, dusky skin, or bullae (necrotizing soft tissue infection)
• Fever, chills, hypotension, or confusion (possible sepsis)
• Spreading redness, warmth, pus, or red streaks beyond initial cellulitis area
• Fever above 38.0 C / 100.4 F or chills
• Bleeding from a bite site lasting more than 24 hours
• Hives, facial or tongue swelling, throat tightness, or breathing difficulty